Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.40 |
| ▸ | CA1 | P00915 | 1/20 | 0.31 |
| ▸ | CA2 | P00918 | 1/20 | 0.31 |
| ▸ | CA4 | P22748 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | HTT | P42858 | 1/20 | 0.30 |
| ▸ | NOS2 | P35228 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19193146 | 1.00 | L3MBTL1 (0.40) | L3MBTL1CA1CA2CA4ALDH1A1 | |
| SCHEMBL27172676 | 0.86 | — | — | |
| SCHEMBL19605815 | 0.86 | — | — | |
| SCHEMBL17049736 | 0.84 | CA1 (0.32) | L3MBTL1CA1CA2CA4NOS2 | |
| SCHEMBL17049737 | 0.84 | CA1 (0.32) | L3MBTL1CA1CA2CA4NOS2 | |
| SCHEMBL7876168 | 0.84 | CA1 (0.32) | L3MBTL1CA1CA2CA4NOS2 | |
| SCHEMBL6936568 | 0.77 | CA1 (0.30) | CA1CA2CA4 | |
| SCHEMBL19193246 | 0.76 | — | — | |
| SCHEMBL24856290 | 0.74 | L3MBTL1 (0.32) | L3MBTL1 | |
| SCHEMBL19193161 | 0.74 | OGA (0.32) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150045422-A1 | Influenza treatment using targeted transient ribosomal inhibition | ZAMOYSKI MARK JOHN (US) | 2015-02-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150045422-A1 | Influenza treatment using targeted transient ribosomal inhibition | EIF2AK2, UPF1, RPL5 | L3MBTL1 271/4885CA1 4873/4885CA2 4817/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.